文献

J-GLOBAL ID：202102261616687163   整理番号：21A0168816

進行または再発胆道癌の全身治療

Systemic treatment of advanced or recurrent biliary tract cancer

著者 (15件)： Zhang Wei (Department of Hepatobiliary Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.) ,  Zhang Wei (National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin. Tianjin’s Clinical Research Center for Cancer, Tianjin, China.) ,  Zhou Hongyuan (Department of Hepatobiliary Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.) ,  Zhou Hongyuan (National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin. Tianjin’s Clinical Research Center for Cancer, Tianjin, China.) ,  Wang Yingying (Department of Hepatobiliary Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.) ,  Wang Yingying (National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin. Tianjin’s Clinical Research Center for Cancer, Tianjin, China.) ,  Zhang Zewu (Department of Hepatobiliary Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.) ,  Zhang Zewu (National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin. Tianjin’s Clinical Research Center for Cancer, Tianjin, China.) ,  Cao Guangtai (Cangzhou Hospital of Integrated TCM-WM Cangzhou, Hebei, China.) ,  Song Tianqiang (Department of Hepatobiliary Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.) ,  Song Tianqiang (National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin. Tianjin’s Clinical Research Center for Cancer, Tianjin, China.) ,  Zhang Ti (Department of Hepatobiliary Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.) ,  Zhang Ti (National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin. Tianjin’s Clinical Research Center for Cancer, Tianjin, China.) ,  Li Qiang (Department of Hepatobiliary Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.) ,  Li Qiang (National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin. Tianjin’s Clinical Research Center for Cancer, Tianjin, China.)
資料名： BioScience Trends  (BioScience Trends)
巻： 14  号： 5  ページ： 328-341(J-STAGE)  発行年： 2020年 
JST資料番号： L8367A  ISSN： 1881-7815  CODEN： BTIRCZ  資料種別： 逐次刊行物 (A)
記事区分： 文献レビュー  発行国： 日本 (JPN)  言語： 英語 (EN)

抄録/ポイント： 胆道癌(BTC)は胆管細胞分化の特徴を有する多様な上皮腫瘍を...

シソーラス用語： *進行癌 ,...
準シソーラス用語： BRAF阻害剤 ,...

ログイン（無料）して見る     続きはJDreamIII（有料）にて  {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=21A0168816&from=J-GLOBAL&jstjournalNo=L8367A") }}

著者キーワード (5件)： 胆道癌 ,  化学療法 ,  標的療法 ,  免疫チェックポイント阻害剤 ,  次世代シークエンシング

分類 (2件)： 消化器の腫よう  (GH04000D) ,  腫ようの薬物療法  (GE03032C)

物質索引 (4件)： イリノテカン ,  ゲムシタビン ,  フルオロウラシル ,  ロイコボリン

引用文献 (95件)：

• 1. Rizvi S, Khan SA, Hallemeier CL, Kelley RK, Gores GJ. Cholangiocarcinoma - Evolving concepts and therapeutic strategies. Nat Rev Clin Oncol. 2018; 15:95-111.
• 2. Saha SK, Zhu AX, Fuchs CS, Brooks GA. Forty-year trends in cholangiocarcinoma incidence in the U.S.: Intrahepatic disease on the rise. Oncologist. 2016; 21:594-599.
• 3. Raoof M, Singh G. Rising trends in intrahepatic cholangiocarcinoma incidence and mortality: getting at the root cause. Hepatobil Surg Nutr. 2019; 8:301-303.
• 4. Taylor-Robinson SD, Toledano MB, Arora S, Keegan TJ, Hargreaves S, Beck A, Khan SA, Elliott P, Thomas HC. Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968-1998. Gut. 2001; 48:816-820.
• 5. Yamamoto S. Biliary tract cancer mortality rates by prefectures in Japan. Jpn J Clin Oncol. 2000; 30:576.

タイトルに関連する用語 (3件)： 再発 ,  胆道癌 ,  全身治療